Progyny, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $PGNY in the last 7 days.
Progyny (PGNY) shares rose 6% after announcing a record 1.2 million new covered lives expected by mid-2027. The company's Q1 2026 revenue guidance of $325.5M missed estimates by 5.1%. Despite a 7.3% YTD gain, shares trade 14.7% below their 52-week high.
Progyny (PGNY) expects to add 1.2 million new covered lives by 2027, driven by employer demand for cost-effective fertility solutions. CEO Pete Anevski attributes growth to employers seeking benefit managers with proven cost management amid rising medical costs. The company offers accelerated contracting for 2027 expansions.
Wells Fargo initiated coverage on Progyny (PGNY) with an Overweight rating and a $37.00 price target. The stock is trading at $24.89, with a GF Value™ of $29.11, indicating a 14.5% undervaluation. PGNY has a GF Score™ of 96/100, reflecting strong financial performance. The company specializes in fertility and women's health benefits management, with a market cap of $1.91 billion.
Recent PGNY coverage spans financial news, earnings and market movers.
In the last 30 days, PGNY insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($154K). The most active reporter was Cummings Melissa B, Chief Operating Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The announcement signals strong demand for Progyny's fertility benefits platform, likely supporting further price appreciation.
Positive growth outlook may lift the stock.
Analyst upgrade to Overweight with a higher price target suggests potential upside.
Insider sale may signal slight downside pressure.
The insider sale may signal reduced confidence, potentially pressuring the stock short-term.
AlphAI scores every news story that mentions PGNY with an AI model for sentiment and relevance, and aggregates insider trades from Progyny, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Progyny (PGNY) shares rose 6% after announcing a record 1.2 million new covered lives expected by mid-2027. The company's Q1 2026 revenue guidance of $325.5M missed estimates by 5.1%. Despite a 7.3% YTD gain, shares trade 14.7% below their 52-week high.
2 min readProgyny (PGNY) expects to add 1.2 million new covered lives by 2027, driven by employer demand for cost-effective fertility solutions. CEO Pete Anevski attributes growth to employers seeking benefit managers with proven cost management amid rising medical costs. The company offers accelerated contracting for 2027 expansions.
2 min readWells Fargo initiated coverage on Progyny (PGNY) with an Overweight rating and a $37.00 price target. The stock is trading at $24.89, with a GF Value™ of $29.11, indicating a 14.5% undervaluation. PGNY has a GF Score™ of 96/100, reflecting strong financial performance. The company specializes in fertility and women's health benefits management, with a market cap of $1.91 billion.
2 min readProgyny director Kevin K. Gordon sold 11,500 shares for $321,358 at $27.94 each. The stock rose 59% in six months. Progyny reported Q2 2026 earnings of $0.55 per share on $350.51M revenue, beating estimates. Citizens raised its price target to $33. Progyny maintains full-year guidance of $1.36B-$1.385B revenue and $2.04-$2.10 EPS.
1 min readGORDON KEVIN K sold 11,500 shares of Progyny, Inc. (PGNY) at $27.94 ($0.32M total) on 2026-09-10.
1 min readProgyny (PGNY) and other health insurers reported Q2 earnings, with revenues beating estimates by 2.8% but guidance below expectations. PGNY's revenue grew 5.3% YoY, missing EBITDA guidance. CVS Health (CVS) reported 7.3% YoY revenue growth, beating estimates. Molina Healthcare (MOH) saw a 4.8% YoY revenue decline. Alignment Healthcare (ALHC) grew 31.6% YoY, while Clover Health (CLOV) saw 55.6% YoY growth. Stocks have declined since earnings, except CLOV, which rose 4.3%.
3 min readCencora (COR) is down 6.7% since reporting Q2 earnings, trading at $97.38. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, dropping 14.1% to $25.94. Humana (HUM) reported $40.87B revenue, up 26.2% YoY, beating estimates, and rose 5% to $407.96. Cigna (CI) reported $71.56B revenue, up 6.6% YoY, beating estimates, but fell 4% to $284.64.
3 min readProgyny (PGNY) presented at the Wells Fargo Healthcare Conference, noting seasonal August softness but expecting a September recovery. The company serves 7.2M lives, with a large addressable market. It adjusted 2024 guidance downward but emphasized long-term growth, new product lines, and strong cash flow. Management highlighted Progyny's leading position in fertility benefits and expansion into women's health. The stock is trading below its Fair Value, with a PEG ratio of 0.46, according to Inv
2 min readCVS Health (CVS) reported $106.1B revenue, up 7.3% YoY, beating estimates. UnitedHealth (UNH) reported $112B revenue, flat YoY, also beating estimates. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, missing guidance. Molina Healthcare (MOH) reported $10.87B revenue, down 4.8% YoY, missing guidance. All stocks have declined since earnings.
3 min readHealthcare stocks have outperformed the S&P 500, but some companies face challenges. Bausch + Lomb (BLCO) has declining EPS and free cash flow margins. Envista (NVST) shows weak sales growth and profitability. Progyny (PGNY) struggles with unit sales and capital returns. All three trade at forward P/E ratios of 16.9x, 17.5x, and 11.8x respectively.
3 min read
